JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
JP Morgan Healthcare Conference, Day 3: Quanterix, Grail, GeneDx
Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of 2025.
JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Labcorp, Hologic, CareDx, More
Highlights from the first day included updates from several firms about their China businesses and M&A strategies.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium
The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.
JP Morgan Healthcare Conference, Day 1: Exact Sciences, Revvity, Qiagen, Guardant Health, Waters
Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and beyond.
Boulud also provided additional information on the company's Q4 performance, noting that it placed 900 SpotFire point-of-care PCR instruments during the quarter.
Clinical customers helped Illumina place 91 NovaSeq X instruments in the fourth quarter. CFO Ankur Dhingra said many planned to use them for MRD testing.